A study of mice bearing tumour xenografts of a human GI tumour line with endogenous MRP2 overexpression demonstrated that inhibiting MRP2 with myricetin increased in vivo sensitisation to oxaliplatin antitumour activity with little or no increase in host toxicity. Here, ABCC2 is linked to digestive system neoplasm.